DMAAU
Drugs Made In America Acquisition Corp. Units
NASDAQ · Financial Services · Financial - Conglomerates · US
$10.83
+0.37%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Expenses | |||
| R&D Expense | — | — | — |
| SG&A Expense | 939.6K | 2.8M | 479.73 |
| General & Admin Expense | 939.6K | 2.8M | 479.73 |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | 1.7M | — | — |
| Total Operating Expenses | 2.6M | 2.8M | 479.73 |
| Cost and Expenses | 2.6M | 2.8M | 479.73 |
| Operating Income (EBIT) | (2.6M) | (2.8M) | (479.00) |
| Non-Operating | |||
| Interest Income | 8.7M | 8.8M | — |
| Interest Expense | — | — | — |
| Net Interest Income | 8.7M | 8.8M | — |
| Other Non-Op Income/Expense | 8.7M | 8.8M | — |
| Non-Operating Income (excl Interest) | — | — | — |
| EBT (Pre-Tax Income) | 6.1M | 5.9M | (479.00) |
| Income Tax Expense | — | — | — |
| Bottom Line | |||
| Net Income | 6.1M | 5.9M | (479.00) |
| Earnings from Cont. Ops | 6.1M | 5.9M | (479.00) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | 6.1M | 5.9M | (479.00) |
| Per Share | |||
| Basic EPS | $0.20 | $0.19 | ($0.06) |
| Diluted EPS | $0.20 | $0.19 | ($0.06) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 |
| Shares | |||
| Basic Shares Outstanding | 20.1M | 21.0M | 8.6M |
| Diluted Shares Outstanding | 20.1M | 21.0M | 8.6M |
| Profitability Metrics | |||
| EBITDA | (2.6M) | (2.8M) | (279.8K) |
| D&A | — | — | 479.73 |
| EBIT | (2.6M) | (2.8M) | (479.00) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026